Anne Truitt, MD
Dermatology · Poway, CANPI 1306096680
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Kerecis Limited at 41.8% of the total. Reporting peaked in 2023 at $1,837 and has fallen 84.7% since, to $280 in 2025.
Across 48 payments — averaging $80.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kerecis Limited$2K
- Almirall LLC$800
- Incyte Corporation$381
- Regeneron Healthcare Solutions, Inc.$251
- Johnson & Johnson$136
- Misonix Inc$133
- plus $538 from 10 others
What the payments were for
- Consulting fees$80021%
- Travel & lodging$1,16930%
- Food & beverage$1,83448%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kerecis Limited | 4 | $1,608 |
| Almirall LLC | 1 | $800 |
| Incyte Corporation | 12 | $381 |
| Regeneron Healthcare Solutions, Inc. | 7 | $251 |
| Johnson & Johnson | 6 | $136 |
| Misonix Inc | 2 | $133 |
| Regeneron | 1 | $126 |
| Hill Dermaceuticals, Inc. | 1 | $110 |
| Pfizer | 4 | $81 |
| Bioventus LLC | 1 | $50 |
| Lilly USA, LLC | 2 | $42 |
| Novartis | 2 | $40 |
| Galderma Laboratories, L.p. | 2 | $34 |
| Integra Lifesciences Corporation | 1 | $25 |
| AbbVie | 1 | $17 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 SurgiClose$4,681
- Kerecis Omega3 GraftGuide$1,560
- Kerecis Omega3 Marigen$1,560
- Klisyri$800
- DUPIXENT$126
- LIBTAYO$121
- Tolak$110
- OPZELURA$101
How this compares
$3,846 in reported general payments places this provider in the 65th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acitretin | 11 | $1,655 |
| Fluorouracil | 12 | $955 |
| Betamethasone Dipropionate | 11 | $358 |
| Ketoconazole | 13 | $219 |
| Doxycycline Hyclate | 19 | $145 |
| Mupirocin | 14 | $108 |
| Triamcinolone Acetonide | 15 | $79 |
| Hydrocortisone | 11 | $55 |
| Famciclovir | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Poway
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.